ARC
VRTX icon

Advisor Resource Council’s Vertex Pharmaceuticals VRTX Stock Holding History

Advisor Resource Council’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-519
Closed -$241K – 269
2024
Q3 		$241K Buy
+519
New +$249K 0.11% 197
2022
Q3 		– Sell
-802
Closed -$226K – 497
2022
Q2 		$226K Buy
+802
New +$215K 0.02% 439

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Advisor Resource Council's VRTX Position: Q4 2024 in Review

Advisor Resource Council sold out of Vertex Pharmaceuticals (VRTX) in Q4 2024, closing a stake of 519 shares — an estimated $241K sold.

Advisor Resource Council first reported a position in VRTX in Q2 2022 and held it in 2 quarters. The position peaked at $241K in Q3 2024. 1,557 funds tracked by Wall St. Rank hold VRTX as of Q4 2024.

  • Advisor Resource Council reported no remaining Vertex Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Advisor Resource Council sold 519 Vertex Pharmaceuticals shares in Q4 2024, an estimated $241K.
  • Advisor Resource Council first reported a position in Vertex Pharmaceuticals in Q2 2022 and held it in 2 quarters.
  • Advisor Resource Council's Vertex Pharmaceuticals position peaked at $241K in Q3 2024.
  • 1,557 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2024.

Based on Advisor Resource Council's 13F filing for Q4 2024, filed 26 Feb 2025.